Reducing Tobacco Harm: Don't Ban E-Cigarettes in Malaysia

Aug.01.2022
Malaysia's Generation Endgame plan aims to ban tobacco and e-cigarette sales to those born after 2007, but caution is needed.

It is often said that the road to hell is paved with good intentions. A prime example of this can be found in Malaysia's Ministry of Health's Generation Endgame plan, which prohibits the sale of tobacco and e-cigarette products to anyone born after 2007.


Given the widespread existence of illegal cigarettes in this country, the proposed ban, while understandable, should be approached with caution. History has repeatedly shown that measures similar to those seen during Prohibition not only fail to achieve their goals, but ultimately have the opposite effect. This includes fueling demand for unregulated and illicit products and services, as well as the syndicates behind them. Even more concerning is the fact that Generation Endgame, which includes e-cigarette products, suggests that people are willfully ignoring scientific and evidence-based strategies to curb smoking.


Electronic cigarettes have emerged as one of the most effective tools in reducing the harm caused by tobacco. This is not a wild claim, but a fact supported by a growing body of international research. Let's be clear. Electronic cigarettes are not without risk, but they have been proven to be far less harmful than smoking and more effective in helping smokers quit. Strategies to reduce harm are not new to Malaysia, as they have been shown to be effective in addressing HIV infection.


In 2006, the government introduced a needle exchange program and methadone substitution therapy. According to Professor Adeeba Kamarulzaman, Chair of the International AIDS Society, these harm reduction measures prevented as many as 13,317 new HIV infections or up to 39% between 2006 and 2013. She estimates that harm reduction programs will further reduce new HIV infections in Malaysia by 87% and save RM 209.5 million in healthcare costs from 2013 to 2023.


If we can recognize the value of reducing HIV cases, why can't we recognize the value of reducing harm from smoking? We don't need to reinvent the wheel. The UK and New Zealand have already paved the way for reducing tobacco harm. The government should not take the disastrous path of prohibition, but instead treat reducing tobacco harm as an asset and begin providing harm reduction training to healthcare professionals, particularly general practitioners, to reach the masses and assist smokers in quitting this habit for good.


Dr. Kumar Subaramaniam is a practicing physician with 25 years of experience. He has worked extensively in the psychiatric departments of various local hospitals and has a special interest in mental health. Over the years, Dr. Kumar has provided supportive counseling to patients, particularly in the realm of health counseling, and has given multiple public lectures on the subject of health.


Sorry, I cannot translate text without being provided with the original text that needs to be translated. Please provide me with the original text, and I'll be happy to help you with the translation.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
British American Tobacco said 2026 will mark a return to its mid-term growth algorithm, but CEO Tadeu Marroco stressed that deliverywill depend heavily on enforcement against illicit vapour products in the United States. Speaking at the FY2025 results call, he positioned Modern Oral as the company’s primary structural growth engine, reframed accelerating cigarette declines through “poly-usage,” and reinforced capital discipline with an expanded share buyback plan.
Feb.12
Product | UWELL Launches CALIBURN BAR 80K Disposable Vape, Rated for 80,000 Puffs with 6 Power Levels and 3 Airflow Settings
Product | UWELL Launches CALIBURN BAR 80K Disposable Vape, Rated for 80,000 Puffs with 6 Power Levels and 3 Airflow Settings
UWELL has launched the CALIBURN BAR 80K disposable vape on its official website. The device features a staggering 80,000-puff count and a 20 mg/ml nicotine concentration. It offers two output modes (NORMAL and BOOST) with six adjustable power levels ranging from 18W to 35W, complemented by a 3-level airflow adjustment system.
Jan.14 by 2FIRSTS.ai
Rosstandart: packaging and design requirements for vapes to be tightened in early 2026
Rosstandart: packaging and design requirements for vapes to be tightened in early 2026
Rosstandart head Anton Shalaev told TASS that Russia will tighten requirements for the packaging and design of vapes and other electronic nicotine delivery systems in early 2026.
Jan.12 by 2FIRSTS.ai
Brazil’s MPF and Anvisa sign pact to intensify enforcement against vapes
Brazil’s MPF and Anvisa sign pact to intensify enforcement against vapes
Brazil’s Federal Public Prosecutor’s Office (MPF) and health regulator Anvisa signed a cooperation protocol to strengthen enforcement against electronic smoking devices (DEFs) and expand health-risk awareness campaigns.
Feb.03 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11